Ann: GENERAL: PEB: Pacific Edge adds to its growing list of issued patents

• Release Date: 18/03/15 09:52
• Summary: GENERAL: PEB: Pacific Edge adds to its growing list of issued patents
• Price Sensitive: No
• Download Document  5.85KB

					PEB
18/03/2015 09:52
GENERAL
NOT PRICE SENSITIVE
REL: 0952 HRS Pacific Edge Limited

GENERAL: PEB: Pacific Edge adds to its growing list of issued patents

18 March 2015

Pacific Edge adds to its growing list of issued patents

Specialist cancer diagnostic company Pacific Edge has been granted further
international patents for two more of its cancer detection technologies.

The NZX-listed company has announced that a patent filed in Japan as part of
its technology targeted to detect stomach cancer has been granted where,
according to the World Cancer Research Fund, stomach cancer is the world's
fifth most common cancer and Japan has the third highest incidence. The same
technology has previously been patented in New Zealand, Australia, China and
Europe. Mexico has granted a patent to Pacific Edge for its technology
essential in the development of one of the company's future products
Cxbladder Predict.

Pacific Edge CEO David Darling says the company's growing patent portfolio is
essential to Pacific Edge's commercial growth and development and is
reflective of the great science underpinning the company's products.

"Our intellectual property is our key asset: securing that is the basis of
our programme to develop diagnostic and prognostic tests that improve the
detection and management of cancer around the world," says David Darling.

"Having patents  in many of our key markets and proposed markets - covering
the Americas, Asia, Europe (38 countries) and Australasia - provides us with
the scope to deliver on our long-term commercial goals and in doing so create
additional value for shareholders."

"While it is important for the company to seek patent protection in key
jurisdictions, our main focus continues to be building sales momentum for
Cxbladder in the US, the world's largest healthcare market, where we have
just now started into our second year of commercial operations. Laboratory
through-put is tracking to the company's expectations following an active
direct sales and marketing program to clinicians and healthcare
organisations. Pacific Edge Diagnostics USA has 12 dedicated sales executives
operating in key geographic regions."

"In tandem with the significant progress we are making with our existing
products, Pacific Edge will continue to develop new detection technologies
for a range of cancers with a view to commercialising those technologies.
Further developments of the Cxbladder technology are underway with the next
product, Cxbladder Triage due to be released in the US this year after its
successful launch in New Zealand. Cxbladder Triage allows clinicians to
segregate patients who have presented to their healthcare provider with
haematuria (blood in the urine, an early indicator of possible bladder
cancer) who have a low probability of having urothelial carcinoma. The use of
this new product - Cxbladder Triage provides upside and cost saving for the
patient, the clinician and the healthcare system to exclude a significant
proportion of these patients from having to have a full clinical work-up for
bladder cancer that is both expensive and invasive."

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

ABOUT PACIFIC EDGE

Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic
company specialising in the discovery and commercialisation of diagnostic and
prognostic technology for the early detection and monitoring of cancer. The
company is developing and commercialising its range of Cxbladder bladder
cancer tests. It's first commercial product, Cxbladder Detect, is now being
actively marketed to physicians and clinicians in New Zealand, Australia, and
the USA through the company's wholly owned subsidiaries and selected
commercial partners.

www.pacificedge.co.nz www.pacificedgedx.com

ABOUT Cxbladder Detect

Cxbladder Detect is a proprietary, accurate molecular diagnostic test that
enables the non-invasive detection of bladder and other urinary tract cancers
from a small volume of urine. Cxbladder Detect is commercially available in
New Zealand, Australia and the USA.  Cxbladder Detect is available in the USA
and NZ as a laboroatory Developed Test (LDT) from the company's CLIA
certified laboratories, providing physicians and clinicians with a quick,
cost effective and accurate measure of the presence of the cancer, and
provides urologists with the opportunity to reduce their reliance on the need
for invasive tests such as cystoscopy. The Cxbladder Detect cancer detection
test has been validated by a multicentre, international clinical study.
www.cxbladder.com

ABOUT Cxbladder Triage

Cxbladder Triage is a novel molecular test that combines the power of the
genomic biomarkers with extra phenotypic and clinical risk biomarkers to
accurately identify and remove patients with haematuria who have a low
probability of bladde cancer, from needing to have a full-urological work-up.
This  is a tool for use by clinicians and physicians in the primary
evaluation and will result in a reduction of the number of patients needing
an expensive and invasive work-up for urothelial cancer.

www.cxbladder.com

ABOUT BLADDER CANCER

Globally, bladder cancer has the 9th highest incidence and the 4th highest
incidence for men. One of the early symptoms of bladder cancer is the
presence of blood in the urine, haematuria. People with haematuria often
present to their general practitioner before being referred on to a
urologist.

Bladder cancer has a very high recurrence rate of approximately 50%-70% with
up to 30% of these recurring as later stage tumours. However, bladder cancers
are highly treatable, especially if detected in the early stages when there
is a much higher probability of survival.  Timely detection and regular
surveillance and monitoring of this cancer is a key element of the clinical
process and of the individual's annual healthcare plan.
End CA:00261998 For:PEB    Type:GENERAL    Time:2015-03-18 09:52:13